DePuy Synthes Expects Healthy Volume Recovery to End 2021

DePuy Synthes reported 3Q21 orthopedic revenue of $2,091 million, +0.5% vs. 3Q20. COVID's Delta variant caused procedure volume deceleration in late July through August. More elective procedures, such as knees and spine, saw the most severe impact. According to company leadership, July and August brought volume declines in the mid-single...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us